Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw its shares drop sharply on Tuesday after the company announced a secondary offering. Arena plans to offer 60 million shares of its common stock at the price of $1.15 per share, with an …
This prospectus supplement and the accompanying base prospectus relate to the offer, issuance and sale from time to time of our common stock having an aggregate offering price of up to $50,000,000 through Citigroup Global Markets …
Stay Tuned! Disclosure: I am/we are long ARNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose …
ARNA stock surged as much as 6.6% in pre-market trading today. It was a welcome reprieve for Arena shareholders, …
Arena Pharmaceuticals, Inc. ( ARNA) was a big mover last session, as the company saw its shares rise nearly 6% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. …
Arena Pharmaceuticals, Inc. ARNA is scheduled to report third-quarter 2016 results on Nov 7, after the market closes. The company met earnings expectations last quarter. Over the four trailing quarters, it has recorded an average positive …
Its shares are up 134% year-to-date. The stock soared in late February after the FDA backed its weight loss drug Qnexa. Arena also develops drugs for cardiovascular, central nervous system, inflammatory and metabolic diseases. Up 71% …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has been on quite a roller coaster ride in 2015. A few weeks ago, ARNA shares roared 76% higher in a single day after positive early-stage trials for an autoimmune disease treatment …
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.